Teva Pharmaceutical Industries Ltd. ADR (TEVA): Price and Financial Metrics

Teva Pharmaceutical Industries Ltd. ADR (TEVA): $9.66

0.16 (-1.63%)

POWR Rating

Component Grades








Add TEVA to Watchlist
Sign Up

TEVA Price/Volume Stats

Current price $9.66 52-week high $11.44
Prev. close $9.82 52-week low $7.09
Day low $9.61 Volume 5,040,542
Day high $9.87 Avg. volume 10,318,331
50-day MA $9.12 Dividend yield N/A
200-day MA $8.86 Market Cap 10.83B

TEVA Stock Price Chart Interactive Chart >


  • Value is the dimension where TEVA ranks best; there it ranks ahead of 97.74% of US stocks.
  • TEVA's strongest trending metric is Growth; it's been moving up over the last 177 days.
  • TEVA's current lowest rank is in the Momentum metric (where it is better than 6.74% of US stocks).

TEVA Stock Summary

  • TEVA has a market capitalization of $9,730,030,033 -- more than approximately 84.19% of US stocks.
  • TEVA PHARMACEUTICAL INDUSTRIES LTD's stock had its IPO on March 26, 1990, making it an older stock than 85.3% of US equities in our set.
  • TEVA PHARMACEUTICAL INDUSTRIES LTD's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is 19.62%, greater than the shareholder yield of 90.21% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to TEVA PHARMACEUTICAL INDUSTRIES LTD are ERJ, PTPI, FLNT, ADTH, and ELAN.
  • TEVA's SEC filings can be seen here. And to visit TEVA PHARMACEUTICAL INDUSTRIES LTD's official web site, go to

TEVA Valuation Summary

  • TEVA's price/earnings ratio is -4.5; this is 118.52% lower than that of the median Healthcare stock.
  • TEVA's price/sales ratio has moved down 5 over the prior 243 months.

Below are key valuation metrics over time for TEVA.

Stock Date P/S P/B P/E EV/EBIT
TEVA 2023-11-03 0.7 1.4 -4.5 -28.9
TEVA 2023-11-02 0.7 1.4 -4.4 -28.7
TEVA 2023-11-01 0.7 1.4 -4.4 -28.7
TEVA 2023-10-31 0.6 1.4 -4.3 -28.5
TEVA 2023-10-30 0.6 1.4 -4.3 -28.4
TEVA 2023-10-27 0.6 1.3 -4.1 -27.9

TEVA Growth Metrics

    The 3 year price growth rate now stands at -42.28%.
  • Its 2 year cash and equivalents growth rate is now at 20.57%.
  • Its year over year cash and equivalents growth rate is now at 24.78%.
Over the past 30 months, TEVA's revenue has gone down $1,557,000,000.

The table below shows TEVA's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-12-31 14,925 1,590 -2,353
2022-09-30 15,142 1,073 -1,290
2022-06-30 15,434 1,059 -1,054
2022-03-31 15,558 1,154 -615
2021-12-31 15,878 798 417
2021-09-30 16,232 673 726

TEVA's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • TEVA has a Quality Grade of C, ranking ahead of 57.93% of graded US stocks.
  • TEVA's asset turnover comes in at 0.33 -- ranking 140th of 682 Pharmaceutical Products stocks.
  • LFVN, ONVO, and ANAB are the stocks whose asset turnover ratios are most correlated with TEVA.

The table below shows TEVA's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.330 0.468 0.064
2021-06-30 0.329 0.469 -0.088
2021-03-31 0.319 0.463 -0.097
2020-12-31 0.316 0.464 -0.102
2020-09-30 0.298 0.471 -0.108
2020-06-30 0.293 0.462 0.018

Teva Pharmaceutical Industries Ltd. ADR (TEVA) Company Bio

Teva Pharmaceutical Industries Ltd is a pharmaceutical company which develops, produces, and markets, generic and specialty medicines which include chemical and therapeutic medicines in a variety of dosage forms and central nervous system medicines. Established in 1901, the company markets 3,500 generic and proprietary products to 60 countries worldwide. Teva competes against other large pharmaceutical companies such as Pfizer, Merck, Novartis, and GlaxoSmithKline. Kare Schulz currently serves as Teva’s President, Chairman of the Board, and Chief Executive Officer, overseeing an international workforce of around 38,000 employees.

TEVA Latest News Stream

Event/Time News Detail
Loading, please wait...

TEVA Latest Social Stream

Loading social stream, please wait...

View Full TEVA Social Stream

Latest TEVA News From Around the Web

Below are the latest news stories about TEVA PHARMACEUTICAL INDUSTRIES LTD that investors may wish to consider to help them evaluate TEVA as an investment opportunity.

Teva to Present at the 6th Annual Evercore ISI HealthCONx Conference

TEL AVIV, Israel, November 20, 2023--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the Evercore ISI HealthCONx Conference on Tuesday, November 28, 2023. The presentation will begin at 8:20 A.M. Eastern Time.

Yahoo | November 20, 2023

Teva Announces Approval of a Generic Version of Forteo® (teriparatide injection), in the U.S.

PARSIPPANY, N.J. & TEL AVIV, Israel, November 17, 2023--Teva Pharmaceuticals Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the approval of a generic version of Forteo®1, in the United States. Market availability of the product in the U.S. is expected in the coming weeks.

Yahoo | November 17, 2023

50 Most Populated Countries in 2030

In this article, we’ll list countries expected to be the most populated in 2030 and their population growth patterns. If you want to skip how the world’s population trends are changing, read 10 Most Populated Countries in 2030. Patterns in the World’s Population Growth As we approach 2030, it is crucial to understand the dynamics […]

Yahoo | November 16, 2023

Alkermes (ALKS) Proprietary Drugs Aid Growth Amid Competition

Alkermes' (ALKS) growth is being driven by the sale of its proprietary products, Vivitrol, Aristada and Lybalvi. However, stiff competition in the target market remains an overhang.

Yahoo | November 14, 2023

TEVA, Royalty Pharma Sign Funding Deal for Schizophrenia Drug

Per the deal, Royalty Pharma is set to provide TEVA R&D funding support of up to $125 million to develop olanzapine LAI for treating schizophrenia.

Yahoo | November 14, 2023

Read More 'TEVA' Stories Here

TEVA Price Returns

1-mo 10.27%
3-mo -1.83%
6-mo 33.61%
1-year 11.03%
3-year 2.66%
5-year -55.15%
YTD 5.92%
2022 13.86%
2021 -16.99%
2020 -1.53%
2019 -36.45%
2018 -18.63%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!